Journal of Shandong University (Health Sciences) ›› 2025, Vol. 63 ›› Issue (12): 1-5.doi: 10.6040/j.issn.1671-7554.0.2025.0494
• Expert Consensus •
Thoracoscopic Committee of Shandong Provincial Endoscopic Surgery Quality Control Center
CLC Number:
| [1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. [2] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. [3] Lin Z, Cheng X. The future and challenges of robotics in lung cancer surgery[J]. Tumor, 2024, 44(6): 631-641. [4] Casiraghi M, Cara A, Mazzella A, et al. 1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience[J]. Lung Cancer, 2024, 195: 107903. doi: 10.1016/j.lungcan.2024.107903 [5] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南 2025[M]. 北京: 人民卫生出版社, 2025. [6] NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 3.2025[EB/OL].(2025-01-14)[2025-04-27]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450. [7] Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1(less than hilar)non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial[J]. J Thorac Cardiovasc Surg, 2011, 141(3): 662-670. [8] Woo W, Shin JI, Kipkorir V, et al. Clinical benefits of lobe-specific lymph node dissection in surgery for NSCLC: a systematic review and Meta-analysis[J]. JTO Clin Res Rep, 2023, 4(5): 100516. doi: 10.1016/j.jtocrr.2023.100516. [9] 孙振国, 岳韦名, 高存, 等. 胸腔镜肺癌手术的质量控制[J]. 中华腔镜外科杂志(电子版), 2020, 13(6): 332-336. [10] Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985. [11] Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer[J]. N Engl J Med, 2023, 389(6): 491-503. [12] Spicer JD, Garassino MC, Wakelee H, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer(KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2024, 404(10459): 1240-1252. [13] Lu S, Zhang W, Wu L, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-Small cell lung cancer: the neotorch randomized clinical trial[J]. JAMA, 2024, 331(3): 201-211. [14] Yue D, Wang W, Liu H, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer(RATIONALE-315): an interim analysis of a randomised clinical trial[J]. Lancet Respir Med, 2025, 13(2): 119-129. [15] Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: final disease-free survival(DFS)and second overall survival(OS)interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer(NSCLC)[J]. Journal of Clinical Oncology, 2024, 42(17_suppl): LBA8035-LBA8035. [16] Wu YL, Dziadziuszko R, Ahn JS, et al. Alectinib in resected ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2024, 390(14): 1265-1276. [17] Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723. [18] Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial[J]. J Clin Oncol, 2023, 41(10): 1830-1840. [19] Hung HY, Tseng YH, Chao HS, et al. Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer[J]. PLoS One, 2020, 15(10): e0236503. doi:10.1371/journal.pone.0236503 [20] Shewale JB, Correa AM, Brown EL, et al. Time trends of perioperative outcomes in early stage non-small cell lung cancer resection oatients[J]. Ann Thorac Surg, 2020, 109(2): 404-411. [21] Andalib A, Ramana-Kumar AV, Bartlett G, et al. Influence of postoperative infectious complications on long-term survival of lung cancer patients: a population-based cohort study[J]. J Thorac Oncol, 2013, 8(5): 554-561. [22] Deslauriers J, Ginsberg RJ, Piantadosi S, et al. Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer[J]. Chest, 1994, 106(6 Suppl): 329s-330s. [23] Yamamichi T, Ichinose J, Omura K, et al. Impact of postoperative complications on the long-term outcome in lung cancer surgery[J]. Surg Today, 2022, 52(9): 1254-1261. |
| [1] | PANG Jinhong, SU Ping, QIAO Junpeng, CHEN Qiaoqiao, CHEN Xueyu, ZHAO Yingying, SHI Jie, SUN Xiaoru, LI Qiuchun, HE Ruiyan, FAN Yiou, CHI Weiwei. Association between modifiable cardiovascular risk factors clustering patterns and stroke in the elderly population [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 11-19. |
| [2] | ZHAO Hanqing, ZHOU Xinrui, LI Zijian, TANG Xing. Application of circulating tumor cells combined with serological detection in non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 79-85. |
| [3] | XU Nianxing, WEI Dong, QIAO Junjie, ZHAN Bingyan. Predictive value of CD8+, IL-6, and PaO2 for immunotherapy-triggered radiation recall pneumonitis in unresectable stage ⅢB/C and IV non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 29-35. |
| [4] | LIU Zhenkun, LYU Jiling, XU Weiwei, MA Litian, ZHANG Caiqing. Value of tNGS testing and conventional culture for BALF in the diagnosis of NSCLC complicated with IPFD [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 36-45. |
| [5] | . Shandong Province expert consensus on multidisciplinary treatment of breast cancer(2024 edition) [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 10-16. |
| [6] | Orthopaedic Rehabilitation Special Committee of Chinese Speaking Orthopaedic Society. Expert consensus on accelerated recovery of knee function after total knee arthroplasty [J]. Journal of Shandong University (Health Sciences), 2024, 62(10): 48-61. |
| [7] | Writing experts: BAN Yanli, ZHAO Ying, LI Hua, LIU Wei, RONG Fengnian, ZHAO Shuping, CUI Baoxia. Expert consensus of practical clinical classification system with optimal surgical strategy for cesarean scar pregnancy [J]. Journal of Shandong University (Health Sciences), 2023, 61(11): 1-10. |
| [8] | WANG Jiongjiong, WANG Guoyong, ZHU Xiaoyan, LI Ling, ZHANG Na, LIU Yunxia. Immediate antiretroviral treatment in 1,926 cases of HIV infection through homosexual transmission in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2023, 61(1): 100-105. |
| [9] | QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82. |
| [10] | CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37. |
| [11] | SUN Yifeng, LI Wei, SUN Shiying, GU Anman, TAN Shengnan, FU Xunye, WANG Haizhi, JI Jianfen, GUAN Yuwang, WU Xiangqian, HE Zhicheng, WEN Zhaoyang, YU Shangjia, LI Shiyi, LIU Xinghong, CHEN Ying, WANG Tingting, SUN Yundong. Changes of antibiotic resistance rates of Morganella morganii in 11 regions of Shandong Province from 2016 to 2021 [J]. Journal of Shandong University (Health Sciences), 2022, 60(12): 88-93. |
| [12] | MA Ruijie, ZHU Liangming, ZUO Taiyang, LI Chunhai, ZHANG Nan, SUN Zhigang. Prognosis of microwave ablation for pulmonary oligometastases after radical resection of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(12): 63-68. |
| [13] | Huining LIU,Jun PENG,Yingchun REN,Guang YANG,Wenhao WANG,Jinfeng LIU,Qing TIAN. Comparison of 34 cases of thoracoscopic wedge resection and 21 cases of segmental resection for stage ⅠA1 non-small cell lung cancer in area P [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 38-43. |
| [14] | DING Zichen, WANG Haohua, ZHOU Liwen, CONG Huiwen, LI Chengsheng, BAO Qihan, YANG Yi, WANG Lianyuan, WANG Suzhen, SHI Fuyan. Study on the individualized efficacy for non-small cell lung cancer patients based on Bayesian Additive Regression Tree model [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 92-98. |
| [15] | TIAN Hui, LI Shuhai, LI Lin, QI Lei, LU Ming, CHENG Chuanle. Quality control of minimally invasive esophagectomy in Qilu Hospital [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 78-82. |
|
||
